Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen plus dexamethasone in relapsed primary AL amyloidosis
MOH_2019-12-23_008545Phase 2Active, not recruiting
- Sponsor
- Oncopeptides AB
- Start
- Dec 2019
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan flufenamide in light-chain amyloidosis, sponsored by Oncopeptides AB. Started Dec 2019; status: active, not recruiting.
02
Drugs
melphalan flufenamide
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2019-12-23_008545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-23_008545.